Food/Drugs/Healthcare/Life Sciences

Stacking the Deck -Again! Clinical Negligence Litigation Cost.

Back in the early part of 2016 I looked at how changes to the costs rules since April 2013 had benefitted Defendants at the expense of Claimants. I pointed out that many had commented that successive governments had been increasingly pro-Defendant in their reforms. The announcement earlier in 2016 by the then Health Minister, Ben… Read More

Recreational Marijuana's Economic Advantages

As Seattle City Attorney Pete Holmes has famously touted, marijuana prohibition and the war on drugs has failed.[1] Evidence does not suggest that the War on Drugs reduced drug-use rates or drug dependency.[2] At any given time, there are at least 137,000 men or women locked in prison or held in jail on drug possession… Read More

The Fate of Pharma Patents in U.S. Inter Partes Review Proceedings

As part of the 2011 America Invents Act,[1] the United States Congress created a new process for challenging the validity of issued U.S. patents in the Patent Office (before the Patent Trial and Appeal Board –“PTAB”).  Known as an Inter Partes Review (“IPR”), this process allows third parties to pursue a “mini-trial” against the validity… Read More

Leaving the EU – what this means for you and your business

Now that the dust is settling on the UK’s decision to leave the EU, our clients are asking what this means for them.  We are the first member state ever to  leave the European Union and as such, the result has ignited much uncertainty and debate about what lies ahead. Change always brings opportunities, as… Read More

New Standards for Cosmetic Surgeons

New GMC Guidelines As of June 2016, new guidance from the GMC regarding doctors carrying out cosmetic procedures will come into force. The new guidelines will highlight the need for accountability from the doctors involved in the treatment, and consideration of patient safety at all times. Various cosmetic procedures have come under fire in the… Read More

Older Entries »